Next Article in Journal
Targeting the Hippo Pathway in Gastric Cancer and Other Malignancies in the Digestive System: From Bench to Bedside
Next Article in Special Issue
The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy
Previous Article in Journal
Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease
Previous Article in Special Issue
Dermatological Autoimmune Considerations of Immune Checkpoint Therapy
 
 
Review

Article Versions Notes

Biomedicines 2022, 10(10), 2511; https://doi.org/10.3390/biomedicines10102511
Action Date Notes Link
article pdf uploaded. 8 October 2022 11:04 CEST Version of Record https://www.mdpi.com/2227-9059/10/10/2511/pdf-vor
article pdf uploaded. 8 October 2022 11:29 CEST Updated version of record https://www.mdpi.com/2227-9059/10/10/2511/pdf-vor
article pdf uploaded. 9 October 2022 06:21 CEST Updated version of record https://www.mdpi.com/2227-9059/10/10/2511/pdf-vor
article xml file uploaded 20 October 2022 12:46 CEST Original file -
article xml uploaded. 20 October 2022 12:46 CEST Update https://www.mdpi.com/2227-9059/10/10/2511/xml
article pdf uploaded. 20 October 2022 12:46 CEST Updated version of record https://www.mdpi.com/2227-9059/10/10/2511/pdf
article html file updated 20 October 2022 12:47 CEST Original file -
article html file updated 28 February 2023 17:04 CET Update -
article html file updated 1 March 2023 20:06 CET Update https://www.mdpi.com/2227-9059/10/10/2511/html
Back to TopTop